The pooled data from all studies revealed that treatment with melatonin did not significantly alter the serum levels of testosterone, LH, and FSH in rodents with metabolic diseases, but subgroup group analysis revealed that the cumulative dose of melatonin and the type of metabolic disease should be considered when interpreting the effect of melatonin on sex hormones. Here, PLOD1 is linked to metabolic disease.